Home › NDC Lookup › RxCUI directory › RxCUI 1046602

Naphazoline hydrochloride 0.5 MG/ML Nasal Solution — RxCUI 1046602

RxNorm drug concept · Semantic clinical drug
RxCUI 1046602 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1046602
Official nameNaphazoline hydrochloride 0.5 MG/ML Nasal Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asnaphazoline hydrochloride 0.05 % Nasal Solution; naphazoline HCl 0.05 % Nasal Solution
FDA products mapped2
Package NDCs mapped2
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Naphazoline hydrochloride 0.5 MG/ML Nasal Soluti... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Naphazoline hydrochloride 0.5 MG/ML Nasal Solution RxCUI 1046602

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Naphazoline 7247
    • Naphazoline hydrochloride 82054
  2. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Naphazoline Nasal Solution 372992
    • Naphazoline hydrochloride Nasal Solution 2649345
    • Naphazoline Nasal Product 1157000
    • Naphazoline hydrochloride Nasal Product 2659746
    • Nasal Solution 316962
    • Nasal Product 1151130
  3. Clinical & branded drugs 1

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Naphazoline hydrochloride 0.5 MG/ML 1043597

Showing up to 8 concepts per family — 9 of 9 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Naphazoline hydrochloride 0.5 MG/ML SCDC · 1043597
  • Naphazoline Nasal Solution SCDF · 372992
  • Naphazoline hydrochloride Nasal Solution SCDFP · 2649345
  • Naphazoline Nasal Product SCDG · 1157000
  • Naphazoline hydrochloride Nasal Product SCDGP · 2659746

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 1046602 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
12539-0146-02 1 BOTTLE, DROPPER in 1 CARTON (12539-146-02) / 14.7868 mL i... NAFASOLINA Doral Pharmamedics Inc DBA AG Marin Pharmaceuticals 2025-03-20
49873-0057-01 1 BOTTLE in 1 CARTON (49873-057-01) / 30 mL in 1 BOTTLE Nazal Sato Pharmaceutical Co., Ltd. 1990-06-11
Observed labelers: Doral Pharmamedics Inc DBA AG Marin Pharmaceuticals (1) · Sato Pharmaceutical Co., Ltd. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.